Precision BioSciences Advances PBGENE-HBV Gene Editing for Chronic Hepatitis B Treatment
- Precision BioSciences is developing PBGENE-HBV therapy for chronic hepatitis B, aiming for a functional cure.
- The ELIMINATE-B trial will target patients currently managed with nucleoside analogues, addressing significant unmet medical needs.
- Regulatory approval is secured, and patient dosing for the trial is expected to begin soon, with data by 2025.
Precision BioSciences Advances Gene Editing Therapy for Chronic Hepatitis B
Precision BioSciences, Inc. is taking significant strides in the fight against chronic hepatitis B with the clinical development of its innovative PBGENE-HBV therapy. Set to be unveiled during a virtual event on November 15, the company plans to present preclinical data and elaborate on the ELIMINATE-B trial, its first-in-human study. Chronic hepatitis B, a major global health issue affecting around 300 million individuals, has limited treatment options, with current therapies only providing a functional cure in less than 3% of cases. The inadequacy of existing solutions, particularly as up to 40% of patients could develop severe liver disease or cancer, amplifies the urgency for effective treatments.
PBGENE-HBV represents a paradigm shift in addressing chronic hepatitis B by targeting both cccDNA and integrated viral DNA within hepatocytes. This dual approach aims to eliminate the virus at its root, potentially allowing for a functional cure rather than merely managing symptoms. CEO Michael Amoroso expresses optimism about the promising preclinical findings, which showcase the therapy's robust safety profile, selectivity, and efficient editing capabilities. The ELIMINATE-B trial will specifically target patients currently managed with nucleoside analogues who are not cured but have their disease controlled, indicating a clear unmet medical need.
With regulatory approval already secured, Precision BioSciences is actively establishing trial sites worldwide and expects to begin patient dosing shortly. The anticipated clinical data from the ELIMINATE-B study is projected to be available by 2025, marking a significant milestone for the company and its mission to improve outcomes for chronic hepatitis B patients. The PBGENE-HBV therapy not only embodies an innovative approach to gene editing but also highlights the potential to transform the treatment landscape for a disease that affects millions globally.
Additional Insights on Industry Impact
The launch of PBGENE-HBV underscores the growing interest in gene editing technologies as solutions for chronic viral infections. Precision BioSciences leverages its proprietary ARCUS® platform to develop in vivo gene editing therapies, positioning itself at the forefront of biopharmaceutical advancements in this arena. The unique mechanism of action of PBGENE-HBV not only differentiates it from existing therapies but also aligns with the increasing demand for more effective treatments in the multi-billion-dollar hepatitis B market.
As the clinical landscape evolves, the successful implementation of the ELIMINATE-B trial could pave the way for further innovations in gene editing and chronic disease management, addressing critical health challenges faced by millions worldwide. Precision BioSciences’ commitment to advancing such therapies highlights the potential for transformative solutions in the biopharmaceutical industry.